Mergers & Acquisitions ·
MiMedx Group, Inc. entered into a definitive Agreement and Plan of Merger with Sanara MedTech Inc., under which MiMedx…
MDXGMimedx Group, Inc.
MiMedx Group, Inc. entered into a definitive Agreement and Plan of Merger with Sanara MedTech Inc., under which MiMedx will acquire Sanara in an all-stock and cash transaction valued at $33.00 per share in cash plus 0.4735 shares of MiMedx common stock for each Sanara share. The deal is supported by a $300 million debt commitment from Hayfin Capital Management LLP to fund the acquisition, contingent upon customary closing conditions including shareholder approval and antitrust clearance. Termination fees are set at approximately $9.66 million payable by Sanara and $22.54 million payable by MiMedx under specific circumstances. MiMedx Group, Inc. operates in the medical technology industry, specializing in the collection, processing, and distribution of allogeneic amniotic membrane products for regenerative medicine.